Zacks: Analysts Expect Jazz Pharmaceuticals PLC (JAZZ) Will Announce Earnings of $1.85 Per Share
Wall Street analysts expect Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) to post $1.85 earnings per share for the current quarter, according to Zacks. Five analysts have made estimates for Jazz Pharmaceuticals PLC’s earnings. The highest EPS estimate is $1.87 and the lowest is $1.83. Jazz Pharmaceuticals PLC posted earnings of $1.80 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 2.8%. The firm is scheduled to issue its next earnings report on Tuesday, August 8th.
According to Zacks, analysts expect that Jazz Pharmaceuticals PLC will report full year earnings of $7.29 per share for the current fiscal year, with EPS estimates ranging from $7.18 to $7.40. For the next financial year, analysts expect that the firm will post earnings of $8.84 per share. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover Jazz Pharmaceuticals PLC.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last released its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $1.41 earnings per share for the quarter, missing the consensus estimate of $1.42 by $0.01. The firm had revenue of $376.10 million during the quarter, compared to analysts’ expectations of $376.58 million. Jazz Pharmaceuticals PLC had a return on equity of 24.65% and a net margin of 26.28%. The business’s revenue was up 11.9% on a year-over-year basis. During the same period last year, the business earned $2.26 earnings per share.
JAZZ has been the subject of a number of research reports. Janney Montgomery Scott raised Jazz Pharmaceuticals PLC from a “neutral” rating to a “buy” rating and increased their target price for the stock from $138.00 to $175.00 in a research note on Thursday, April 6th. Cowen and Company reissued an “outperform” rating and set a $190.00 target price on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, June 7th. BidaskClub raised Jazz Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research note on Saturday, June 10th. Mizuho reissued a “buy” rating and set a $162.00 target price (up from $152.00) on shares of Jazz Pharmaceuticals PLC in a research note on Tuesday, March 21st. Finally, Vetr cut Jazz Pharmaceuticals PLC from a “strong-buy” rating to a “buy” rating and set a $161.19 target price for the company. in a research note on Monday, March 20th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seventeen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $183.22.
In other Jazz Pharmaceuticals PLC news, SVP Michael Patrick Miller sold 200 shares of the stock in a transaction on Monday, April 17th. The stock was sold at an average price of $152.56, for a total transaction of $30,512.00. Following the transaction, the senior vice president now owns 22,562 shares in the company, valued at approximately $3,442,058.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction on Tuesday, April 11th. The stock was sold at an average price of $152.12, for a total value of $152,120.00. Following the transaction, the chief executive officer now owns 308,491 shares in the company, valued at approximately $46,927,650.92. The disclosure for this sale can be found here. Insiders have sold a total of 43,295 shares of company stock valued at $6,668,658 in the last ninety days. Insiders own 4.30% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of JAZZ. Envestnet Asset Management Inc. boosted its position in Jazz Pharmaceuticals PLC by 43.0% in the first quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock valued at $141,000 after buying an additional 295 shares during the last quarter. World Asset Management Inc purchased a new position in Jazz Pharmaceuticals PLC during the first quarter valued at $205,000. Bridges Investment Management Inc. purchased a new position in Jazz Pharmaceuticals PLC during the first quarter valued at $208,000. Private Advisor Group LLC purchased a new position in Jazz Pharmaceuticals PLC during the first quarter valued at $215,000. Finally, Logan Capital Management Inc. purchased a new position in Jazz Pharmaceuticals PLC during the first quarter valued at $223,000. Hedge funds and other institutional investors own 86.34% of the company’s stock.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded down 0.87% during mid-day trading on Monday, hitting $153.14. 338,953 shares of the company traded hands. The company’s 50-day moving average price is $151.80 and its 200 day moving average price is $138.04. Jazz Pharmaceuticals PLC has a one year low of $95.80 and a one year high of $163.75. The company has a market capitalization of $9.19 billion, a price-to-earnings ratio of 23.14 and a beta of 1.11.
Jazz Pharmaceuticals PLC Company Profile
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.